jRCT2080222857未知3 期
The long term administration study of MRQ-01 in the cancer patients with breakthrough pain
试验速览
- 阶段
- 3 期
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 干预模型
- Multicenter : open-label, uncontrolled
入排标准
- 年龄范围
- 20age old over 至 No limit（—）
- 性别
- All
入选标准
- •The cancer-related breakthrough pain which rescue needs
排除标准
- 未提供
研究者
相似试验
未知
3 期
The long term administration study of MRQ-01 in the cancer patients with breakthrough paiJPRN-jRCT2080222857Maruishi Pharmaceutical Co., Ltd.50
已完成
3 期
A multicentre, long-term trial of KN01 in patients with MELASJPRN-UMIN000019195Kawasaki Medical School Hospital9
进行中（未招募）
不适用
A Phase 2 Study of ARQ 197 in Patients with Microphthalmia Transcription Factor Associated TumorsEUCTR2009-011669-10-GBArQule, Inc.39
已完成
3 期
A multicentre, long-term administration study of KN01 in patients with mitochondrial encephalomyopathy(MELAS)JPRN-UMIN000015538Kawasaki Medical School Hospital10
进行中（未招募）
1 期
A long term study of the safety of BMN 701 in patients with POMPE diseaseMedDRA version: 18.0Level: LLTClassification code 10036143Term: Pompe's diseaseSystem Organ Class: 100000004850POMPE diseaseEUCTR2011-001805-28-DEBioMarin Pharmaceutical Inc21